Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

5 clinical studies listed.

Filters:

Pheochromocytoma and Paraganglioma (PPGL)

Tundra lists 5 Pheochromocytoma and Paraganglioma (PPGL) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ENROLLING BY INVITATION

NCT06870396

National Study of Adrenal Tumours

This is a study putting together large numbers of patients with or without a hereditary risk of adrenal tumours including tumours such as adrenocortical carcinoma and phaeochromocytoma/paraganglioma. The purpose is to answer questions about the survival of patients with these rare tumours and to do this, we will collect information on diagnosis and management of these tumours. This data will be best assessed by combing these rare cases at a national level recruiting from centres throughout UK and Ireland. The information will be confidential and stored in a secure platform. Patients will be approached for consent to gather their data by their local consultants and patients will have the choice to participate or decline participation, which will not affect their standard of care treatment.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-17

1 state

Pheochromocytoma and Paraganglioma (PPGL)
Adrenocorticol Cancer (ACC)
Adrenal Tumours
RECRUITING

NCT07920198

Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)

Primary Objective: The primary objective of the study is to characterize subjects affected by adrenal disease by collecting medical history data at diagnosis, clinical, bio-humoral, and radiological data, as well as information regarding the therapeutic approach, in terms of both potential surgical interventions and/or pharmacological therapies and hormone replacement therapies. Secondary Objective: The secondary objective is to integrate these data with current knowledge in order to improve the clinical, diagnostic, and therapeutic management of patients affected by adrenal disease, as well as to identify risk and/or predisposing factors for the development of the disease. Study Design: Observational, longitudinal, single-center, non-interventional (without drug administration) study. The study is divided into two phases: FIRST PHASE (retrospective): registration of all patients affected by hypothalamic-pituitary-adrenal disease followed by the Adrenal Diseases Outpatient Clinic of the Endocrinology Unit at the AOU of Modena. SECOND PHASE (prospective): enrollment of all patients affected by adrenal disease consecutively presenting to the Adrenal Diseases Outpatient Clinic of the Endocrinology Unit at the AOU of Modena. Study Population Inclusion criteria: subjects affected by adrenal disease presenting to the Adrenal Diseases Outpatient Clinic of the Endocrinology Unit at the AOU of Modena, who are able to autonomously provide written informed consent. Exclusion criteria: subjects under 18 years of age. Study Methodologies An anonymized database will be created to collect data from patients presenting to the aforementioned outpatient clinic. Specifically, the data collected for each patient will include: demographic data, data related to the adrenal disease, symptoms, physical examination, radiological imaging, surgical intervention data, histological examination data, bio-humoral tests, hormonal tests, DEXA data, current replacement therapies data, current anti-secretory medical therapies data, data on other current pharmacological therapies, and comorbidities data.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-09

1 state

Cushing s Syndrome
Cushing Disease
Cushing Disease Due to Increased ACTH Secretion
+19
RECRUITING

NCT07907341

Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)

It is preliminarily clarified that belzutifan exerts an inhibitory effect on catecholamine synthesis in pheochromocytoma and paraganglioma (PPGL), and its safety is simultaneously confirmed, thereby providing preliminary experimental results for the further exploration of belzutifan as a perioperative preparation drug for patients with PPGL.

Gender: All

Ages: 14 Years - 85 Years

Updated: 2026-10-30

1 state

Pheochromocytoma and Paraganglioma (PPGL)
COMPLETED

NCT07412158

The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom(PPGL)

This study aimed to develop the imaging-based IUPU-PPGL score and evaluate its ability to stratify surgical complexity and its association with perioperative outcomes.

Gender: All

Ages: 18 Years - 85 Years

Updated: 2026-09-28

Risk Grading System
Pheochromocytoma and Paraganglioma (PPGL)
Quantitative Assessment
RECRUITING

NCT07680205

An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'. The study aims to identify changes in the production and metabolism of catecholamines by measuring the substance which starts the chain of catecholamine metabolism called tyrosine in patients before, during and after 5 days of taking Belzutifan 120mg daily.

Gender: All

Updated: 2026-07-02

1 state

Pheochromocytoma and Paraganglioma (PPGL)
Pheochromocytoma Malignant
Pheochromocytoma, Metastatic
+2